Bionxt has completed manufacturing of a batch of BNT23001, its under-the-tongue formulation of cladribine, for use in MS ...
MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it ...
Nurix Therapeutics, Inc. (NRIX) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 1:30 PM EDTCompany ParticipantsArthur Sands - ...
Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC diag ...
Scientists have uncovered a surprising twist in how bacteria share genes—including those that spread antibiotic resistance.
As we age, our ability to maintain healthy blood and a strong immune system gradually declines, largely because hematopoietic ...
3hon MSN
Catching a scramblase in the act could pave the way to improved blood disorder and cancer treatments
Weill Cornell Medicine investigators have revealed the detailed workings of a cell membrane protein that has essential roles ...
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results